Opinion|Videos|October 7, 2024
Patient Selection for Chemotherapy-Based Combination Regimens in Metastatic Prostate Cancer
Author(s)Fred Saad, CQ, MD, FRCS, FCAHS
Key Takeaways
- Chemotherapy is often selected for aggressive or advanced-stage cancers requiring rapid tumor reduction.
- Patients with specific genetic mutations may benefit more from targeted therapies than chemotherapy.
The panelist discusses how patient characteristics, disease factors, and individual health status guide the decision to include or avoid chemotherapy in combination treatments for metastatic prostate cancer, weighing potential benefits against risks and quality of life considerations.
Advertisement
Video Content above is prompted by the following:
- For which patients would you choose or avoid a combination that includes chemotherapy?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves sildenafil oral film for men with erectile dysfunction
2
The UroOnc Minute: Adjuvant Therapy in Renal Cell Carcinoma, with Brian Shuch, MD
3
Pearls & Perspectives: Modern Semen Testing and Male Fertility Care, with Thomas Masterson, MD
4
Head-to-head analysis shows OS benefit with apalutamide vs darolutamide in mCSPC
5